# Alcon agrees to acquire LENSAR for up to $430 million

Alcon announced a definitive merger agreement to acquire LENSAR, Inc. for $14.00 per share in cash (approx. $356 million), plus a contingent value right of up to $2.75 per share, for total potential consideration of up to $430 million. The acquisition includes the ALLY Robotic Cataract Laser Treatment System.

- Type: Acquisition
- Announced: 2025-03-24
- Where: United States
- Value: $356.0M
- Status: announced
- Products: ALLY Robotic Cataract Laser Treatment System, femtosecond laser-assisted cataract surgery equipment
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Alcon Group](https://endata.com/companies/16712.md) (acquirer)
- [LENSAR](https://endata.com/companies/83661.md) (target)

## Sources

- [investor.alcon.com](https://investor.alcon.com/news-and-events/press-releases/news-details/2025/Alcon-Agrees-to-Acquire-LENSAR-Inc-/default.aspx), 2025-03-24: "Alcon will purchase all outstanding shares of LENSAR for $14.00 per share in cash (an aggregate implied value of approximately $356 million)."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.